POSSIBILITIES OF MATRIX METALLOPROTEINASES AS KEY ROLE IN CERVICAL CARCINOGENESIS: A NORTH INDIAN STUDY
Keywords:
MMP-2= matrix metalloproteinases-2, MMP-9= matrix metalloproteinases-9, TIMP-2 = tissue inhibitor of metalloproteinases-2, CC=cancer cervix, CIN= cervical intraepithelial neoplasia.Abstract
Objectives- We aimed to evaluate the levels of circulating MMP-2, MMP-9 and TIMP-2 in pre-invasive stage patients, cervical carcinoma patients and healthy women.
Methods - It was hospital based case-control study conducted at Department of Obstetrics and Gynaecology, King George’s Medical University, Lucknow, India. Included numbers of cases were 84 with equal number of controls. Diagnosis of cases was made through biopsy – proven cervical intra-epithelial neoplasia or cervical cancer. Peripheral blood samples were collected from cases and controls. Expression was evaluated in serum samples by ELISA method.
Results- Significant differences were found in the serum levels of total MMP-2 in cases as compared to healthy controls (P<0.05). (CIN I 200.70 ± 2.45 ng/ml = 137.77±9.59, p value= 0.000), CIN II (257.00±23.96 = 137.77±9.59, p value= 0.000), CIN III (249.40±5.21 = 137.77±9.59, p value= 0.000) and in CC
(318.41± 10.17 = 137.77±9.59, p value= 0.000). Significant differences were also found in the serum levels of total TIMP-2 in CIN I (315.90 ± 6.40 pg/ml = 332.94± 14.46, p value= 0.000), CIN II (225.10±11.90 = 332.94 ± 14.46, p value= 0.000), CINIII (189.80± 4.96 = 332.94± 14.46, p value= 0.000) and in CC (148.94 ± 11.00 = 332.94± 14.46, p value= 0.000).
Conclusion- In the present study we conclude that mmp-2 and TIMP-2 may play role in progression in cervical carcinogenesis in North Indian population.
Downloads
References
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S. and others. (2013). GLOBOCAN 2012 v1.0,: IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon, France.
Forouzanfar M H, Foreman K J, Delossantos A M, Lozano R, Lopez A D., and others. (2011) The Lancet 378 (9801): 1461–84.
Arbyn M, Castellsague X, Sanjose S de, Bruni L, Saraiya M., and others. (2011) Annals of Oncology 22 (12): 2675–86.
Walboomers J M, Jacobs M V, Manos M M, Bosch F X, Kummer J A., and others. (1999) Journal of Pathology 189 12–19.
Vineeta Gupta,1 Manish Kumar Singh,1 Ravindra Kumar Garg,2 Kamlesh Kumar Pant,1 and Sanjay Khattri1.(2013).online DOI:
3109/00207454.2013.824438.
Pia VIHINEN and Veli-Matti K¨AH¨ARI. ( 2002 )4 Int. J. Cancer: 99, 157–166.
Egeblad M and Werb Z.(2002) Nat Rev 2: 163-176, 2002.
Reich R, Thompson E, Iwamoto Y, Martin OR, Deason JR, Fuller OC and Miskin R.(1988) Cancer Res 48: 3307-33121, 1988.
Liotta LA, Steeg PS and Stetler-Stevenson WO. (1991) Cell 64: 327-336.
Hrabec E, Naduk J, Stręk M, et al. (2007) Adv Biochem 2007; 53: 37-45.
Nagase H.(1996) Hooper NM (ed). Taylor & Francis, London, pp153-204.
Fini ME, Cook JR, Mohan R and Brinckerhoft CE. (1998) Academic Press, San Diego, pp299-356, 1998.
Lace MJ, Anson JR, Turek LP, Haugen TH. (2008) J Virol 2008;82:10724-34.
Talvensaari-Mattila Anne1 and Turpeenniemi-Hujanen Taina. (2010) Hindawi Publishing Corporation.Obstetrics and Gynecology International Volume 2010, Article ID 179351, 3 pages.
Yang SF, Wang PH, Lin LY, Ko JL, Chen GD, Yang JS, Lee HS, Hsieh YS.(2007) Reprod Sci. 2007 Oct;14(7):710-8.
Asha Nair S, Karunagaran D, Nair MB, Sudhakaran PR. J Cancer Res Clin Oncol. (2003) Feb;129(2):123-31. Epub 2003 Feb 19.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
.